Compare Ecolab Inc. (ECL) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Hims and Hers Health Inc — how do they compare? Ecolab Inc. trades at $281.42 (market cap $78.97B), while Hims and Hers Health Inc trades at $30.88 (market cap $6.55B). The key difference: Ecolab Inc. is far larger — about 12.1× Hims and Hers Health Inc's market cap, and Ecolab Inc. pays a 1.04% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 90 Days and Hims and Hers Health Inc for 21 Days on average.
| ECL | HIMS | |
|---|---|---|
Market Cap | $78.97B | $6.55B |
Volume | 974,947 | 14,842,814 |
Sector | Basic Materials | Health |
52-Week High | $308.35 | $62.76 |
52-Week Low | $245.73 | $14.52 |
Typical Hold Time | 90 Days | 21 Days |
Enterprise Value | $87.75B | $7.25B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $282.21, up 1.48% today, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with 2025 revenue of $16.08B, net income of $2.08B, and a 12.57% net margin. Recent news highlights its dividend aristocrat status and growth in high-tech segments, while institutional buying and insider purchases reflect confidence.
Outlook is positive given earnings beats, dividend reliability, and strategic expansions like the CoolIT deal, though rising debt and cost pressures pose risks. With a consensus price target of $326.38 implying 16% upside, ECL offers growth potential but requires monitoring of leverage and execution.
Hims & Hers Health trades at $30.12, up 1.96% on the day, amid a bearish technical outlook and mixed fundamentals. The stock faces headwinds from a securities class action lawsuit related to an FTC complaint, with multiple law firms alerting investors ahead of a November 2, 2026 deadline. Financially, revenue grew to $2.35 billion in 2025, but net income turned negative in 2026, with a net loss of $142 million and a profit margin of -5.51%. Analyst consensus is a 'Hold' with a $32.17 price target, indicating limited upside from current levels.
The outlook for HIMS is cautious due to legal overhangs and profitability challenges. Investment opportunities hinge on resolving regulatory issues and returning to earnings growth, but risks include prolonged litigation, competitive pressures, and execution missteps. The stock's high valuation multiples, such as a P/E of 57.14, add vulnerability if growth disappoints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
